Recombinant Human Protein Wnt-10A (WNT10A) Protein (His)

Name: Recombinant Human Protein Wnt-10A (WNT10A) Protein (His)
Brand: Beta LifeScience
SKU: BLC-04511P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Protein Wnt-10A (WNT10A) Protein (His) is produced by our Yeast expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q9GZT5
Target Symbol	WNT10A
Synonyms	FLJ14301; OODD; Protein Wnt-10a; SSPS; STHAG4; Wingless type MMTV integration site family member 10A; WN10A_HUMAN; wnt10a
Species	Homo sapiens (Human)
Expression System	Yeast
Tag	N-6His
Target Protein Sequence	MPRSAPNDILDLRLPPEPVLNANTVCLTLPGLSRRQMEVCVRHPDVAASAIQGIQIAIHECQHQFRDQRWNCSSLETRNKIPYESPIFSRGFRESAFAYAIAAAGVVHAVSNACALGKLKACGCDASRRGDEEAFRRKLHRLQLDALQRGKGLSHGVPEHPALPTASPGLQDSWEWGGCSPDMGFGERFSKDFLDSREPHRDIHARMRLHNNRVGRQAVMENMRRKCKCHGTSGSCQLKTCWQVTPEFRTVGALLRSRFHRATLIRPHNRNGGQLEPGPAGAPSPAPGAPGPRRRASPADLVYFEKSPDFCEREPRLDSAGTVGRLCNKSSAGSDGCGSMCCGRGHNILRQTRSERCHCRFHWCCFVVCEECRITEWVSVCK
Expression Range	36-417aa
Protein Length	Full Length of Mature Protein
Mol. Weight	44.4kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Ligand for members of the frizzled family of seven transmembrane receptors. Functions in the canonical Wnt/beta-catenin signaling pathway. Plays a role in normal ectoderm development. Required for normal tooth development. Required for normal postnatal development and maintenance of tongue papillae and sweat ducts. Required for normal proliferation of basal cells in tongue filiform papillae, plantar epithelium and sweat ducts. Required for normal expression of keratins in tongue papillae. Required for normal expression of KRT9 in foot plant epithelium. Required for normal hair follicle function.
Subcellular Location	Secreted, extracellular space, extracellular matrix. Secreted.
Protein Families	Wnt family
Database References	HGNC: 13829 OMIM: 150400 KEGG: hsa:80326 STRING: 9606.ENSP00000258411 UniGene: PMID: 30096107 Human and mouse WNT10A mutant palmoplantar and tongue epithelia also display specific differentiation defects that are mimicked by loss of the transcription factor KLF4. PMID: 28589954 WNT10a rs201002930 significantly decreased the risk of cleft lip with cleft palate and cleft palate only. PMID: 29356097 WNT10A mutation is associated with tooth agenesis. PMID: 30046887 High WNT10A expression is associated with papillary thyroid carcinoma. PMID: 28677753 Mild to severe oligodontia was observed in all patients bearing biallelic WNT10A mutations. PMID: 28105635 The development of maxillary canine, maxillary second molar and mandibular second molar was statistically significantly delayed in patients with WNT10A variants compared with patients without variants. The impact of WNT10A variants on dental development increases with presence of the nonsense c.(321C>A p.(C107*)) variant and the number of missing teeth PMID: 27650966 Results from genetic analysis revealed that all seven individuals were homozygous or compound heterozygous for WNT10A mutations suggesting that tooth agenesis and/or peg-shaped crowns of primary mandibular incisors, severe oligodontia of permanent dentition as well as ectodermal symptoms of varying severity may be predictors of bi-allelic WNT10A mutations of importance for diagnosis, counselling and follow-up. PMID: 27881089 miR-378a-3p suppresses hepatic stellate cell activation, at least in part, via targeting of Wnt10a, supporting its potential utility as a novel therapeutic target for liver fibrosis. PMID: 27832641 Wnt10a/beta-catenin signaling pathway is able to exacerbate keloid cell proliferation and inhibit the apoptosis of keloid cells through its interaction with TERT. PMID: 27771714 risk of hypodontia may be related to the WNT10A polymorphism. Our results also confirm the importance of the Wnt pathway in tooth development. PMID: 27050986 WNT10A promotes the proliferation of DPCs and negatively regulates their odontoblastic differentiation. PMID: 25134734 WNT10A exonic variant increases the risk of keratoconus by decreasing corneal thickness PMID: 26049155 p.Arg113Cys, p.Phe228Ile, newly identified p.Arg171Leu may represent aetiological mutations underlying MLIA w/associated dental anomalies, implicating coding variants in WNT10A gene PMID: 25545742 this study demonstrated that common variations in WNT10A have pleiotropic effects on the morphology of ectodermal appendages. PMID: 25612571 WNT10A may induce kidney fibrosis and associate with kidney dysfunction in acute interstitial nephritis. PMID: 25054240 transmission disequilibrium test showed transmitted disequilibrium in C392T. we found an association between the C392T variant and nonsyndromic oral clefts. PMID: 24957471 High WNT10A expression promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma PMID: 25795715 Patients with bi-allelic WNT10A mutations have severe tooth agenesis. PMID: 24700731 The novel c.-14_7delinsC mutation might be the etiological variant of the WNT10A gene responsible for the permanent tooth agenesis in the Egyptian family. PMID: 24798981 Barrel-shaped mandibular incisors and severe hypodontia appear to be associated with homozygous or compound heterozygous mutations of WNT10A. PMID: 24458874 Our study has demonstrated for the first time that agenesis of the maxillary permanent canines is a distinct entity, associated with mutations in WNT10A. PMID: 24311251 WNT10A mutations account for (1/4) of population-based isolated oligodontia and show phenotypic correlations. PMID: 24449199 WNT10A and EDA digenic mutations could result in oligodontia and syndromic tooth agenesis in the Chinese population. Moreover, our results will greatly expand the genotypic spectrum of tooth agenesis. PMID: 24312213 involvement of PAX9, EDA, SPRY2, SPRY4, and WNT10A as risk factors for MLIA. uncovered 3 strong synergistic interactions between MLIA liability and MSX1-TGFA, AXIN2-TGFA, and SPRY2-SPRY4 gene pairs. 1st evidence of sprouty genes in MLIA susceptibility. PMID: 24554542 Nine pathogenic mutations within the coding region of the WNT10A gene were identified in 26 out of 42 (62%) Polish patients with non-syndromic tooth agenesis. PMID: 23167694 WNT10A variants were associated with non-syndromic tooth agenesis from mild to severe tooth agenesis, and the more severe tooth agenesis, the stronger association. PMID: 24043634 Mutations in WNT10A are frequently involved in oligodontia associated with minor signs of ectodermal dysplasia. PMID: 23401279 Expression studies in human hair follicle tissue suggests that WNT10A has a functional role in androgenetic alopecia etiology. PMID: 23358095 the expression level of Wnt10a is higher in endometrioid carcinoma than in non-endometrioid subtypes; however, the underlying mechanism remains unclear. PMID: 23135473 WNT10A acts as an autocrine oncogene both in renal cell carcinoma carcinogenesis and progression by activating WNT/beta-catenin signaling. PMID: 23094073 In a panel of 34 patients with isolated hypodontia, the candidate gene WNT10A and the genes MSX1, PAX9, IRF6 and AXIN2 have been sequenced. WNT10A mutations were identified in 56% of the cases with non-syndromic hypodontia. PMID: 22581971 patients harboring WNT10A mutations displayed distinctive clinical features (marked dental phenotype, no facial dysmorphism) PMID: 20979233 We observed a marginally significant interaction between WNT10 rs10177996 (intron 1) and an individual's proportion of calories from saturated fat. PMID: 21547848 Case Reports: Single pedigree study provides a detailed illustration of the phenotypic spectrum of ectodermal abnormalities associated with WNT10A gene pathology. PMID: 21279306 WNT10A may be a novel angio/stromagenic growth factor PMID: 21203463 Mutations in the WNT10A gene are associated with ectodermal dysplasia presenting as palmoplantar keratoderma in two families. PMID: 21143469 The first inherited missense mutation in WNT10A with associated ectodermal features, is reported. PMID: 19471313 c.697G-->T (p.Glu233X) homozygous nonsense mutation in exon 3 of the WNT10A gene in an autosomal recessive ectodermal dysplasia: odonto-onycho-dermal dysplasia PMID: 17847007 mantle cell lymphoma highly and consistently expressed Wnt3 and Wnt10. PMID: 18787224 Study reports on 12 patients, from 11 unrelated families, with ectodermal dysplasia caused by five previously undescribed WNT10A mutations PMID: 19559398

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human Protein Wnt-10A (WNT10A) Protein (His)

Recombinant Human Protein Wnt-10A (WNT10A) Protein (His)

Product Overview

Target Details

FAQs